Not really. They had a trial that missed an important endpoint(failed) the same day as Merck came out with spectacular results in the same field. They'll need to do another financing soon and with the stock price this weak it will be very dilutive. To boot, their drug has significant side effect issues as well, and don't get me started on the CEO who I think is really really awful.
In my opinion, it's a dead duck. I've advised all my friends to sell and stay away for good. This one has been a disaster and will very likely continue to be.